CMConnie Marras

Connie Marras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Connie Marras has a total of 645 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Measuring what matters: Evaluating quality of life instruments through the eyes of people with Parkinson's disease

    by Samantha Dorrance, Richa Patel, Glenn T Stebbins, Jamie L Adams, Allison Allen, Tara Hastings, Soania Mathur, Onanong Phokaewvarangkul, Gary Rafaloff, Rajasumi Rajalingam, et al.

    Background: Many instruments are used to assess quality of life in people living with Parkinson's disease. However, there is limited understanding of what people living with Parkinson's consider relevant and important when measuring quality of life. Aim: To explore what people living with Parkinson's consider relevant and important in the assessment of quality of life. Methods: Semi-structured interviews were conducted with 31 people living with Parkinson's disease. Participants completed eight instruments, which were used to guide discussion and reflection on what helps and what hinders measuring quality of life in a way that is meaningful to them. Results: Participants highlighted a number of features they consider important in the assessment of quality of life. These include being able to select from a wide range of response options, addressing the personal, emotional, and practical impacts of issues, using clear, specific language, and including a balance of questions that address both positive and negative aspects of the Parkinson's experience. Conclusions: There is a need for instruments that reflect the complex and varied ways Parkinson's disease affects individuals. While existing questionnaires incorporate some features that support meaningful assessment, participants also identified features that may hinder the extent to which quality of life is adequately captured and that warrant further refinement. Incorporating feedback from people with lived experience may help inform future evaluation and refinement of quality of life measures in research and care.

  • Open Access

    Cortical myoclonus as a common and clinically actionable movement disorder phenotype of 22q11.2 deletion syndrome

    by Nikolai Gil D. Reyes, Talyta Grippe, Victor S.T. Lira, Benedetta Angeloni, Naaz Desai, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Danielle M. Andrade, et al.

  • Open Access

    Early‐Onset Parkinson's Disease with 22q11.2 Microdeletion and Pathogenic GBA1 Variant

    by Nikolai Gil D. Reyes, Daniel G. Di Luca, Ivan Martinez‐Valbuena, Erik Boot, Maria Corral, Ryan K.C. Yuen, Connie Marras, Anthony E. Lang, Anne S. Bassett

  • Open Access

    Essential genetic testing in movement disorders – results from a Delphi study

    by Vanessa Carvalho, Leonor Correia Guedes, Emilia Gatto, Mayela Rodriguez-Violante, Christine Klein, Federico Rodriguez-Porcel, Francesca Morgante, Malco Rossi, Marcelo Miranda, Christos Ganos, et al.


  • Reply to: “Revisiting Nomenclature in Movement Disorders: The Boundaries Between Pragmatism, Academicism, and Practical Applicability”

    by Connie Marras, Alberto Albanese, Christine Klein, Katja Lohmann, Hyder A. Jinnah

  • Open Access

    MDSGene Systematic Review of Common Forms of Dominant Hereditary Spastic Paraplegia: Novel Insights

    by Ce Kang, Rajasumi Rajalingam, Zachary Walls, Jana Huang, Christine Sun, Laura I. Rudaks, Dennis Yeow, Ashar Rasheed, Jenny W. Zhang, Moath Hamed, et al.

    Background: Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder characterized by progressive spasticity and lower limb weakness. The most common forms of autosomal dominant HSP are caused by pathogenic variants in SPAST (SPG4 or HSP‐ SPAST ), ATL1 (SPG3A or HSP‐ ATL1 ), and REEP1 (SPG31 or HSP‐ REEP1 ). Objectives: We performed an MDSGene Systematic Review to determine in‐depth genotype–phenotype associations and to estimate longitudinal progression, to inform prognostication and clinical trial stratification. Methods: We systematically collected demographic, phenotypic, and genetic data from published reports of individuals affected by these forms of HSP using the MDSGene protocol. Results: We reviewed 2177 affected individuals, including 1670 individuals with HSP‐ SPAST , 356 with HSP‐ ATL1 and 151 with HSP‐ REEP1 . HSP‐ ATL1 was associated with an earlier age at onset compared to HSP‐ SPAST and HSP‐ REEP1 . Toe‐walking was more frequently reported in HSP‐ ATL1 (10.4%) and HSP‐ REEP1 (3.3%) than HSP‐ SPAST (0.3%). Upper limb hyperreflexia and abnormalities of bladder function were more frequent in HSP‐ SPAST than HSP‐ ATL1 or HSP‐ REEP1 . Sufficient data was available to estimate disease progression for HSP‐ SPAST ; this showed that Spastic Paraplegia Rating Scale (SPRS) scores increased with increasing age at examination after the age of 40 years. Truncating variants were more frequent in HSP‐ SPAST and HSP‐ REEP1 than HSP‐ ATL1 . Conclusion: Overall, HSP‐ ATL1 , HSP‐ SPAST and HSP‐ REEP1 demonstrated differences in clinical phenotypes. To our knowledge, this is the first systematic review to model longitudinal progression using SPRS scores in HSP. Missing data is a limiting factor in all these comparisons, highlighting the need for uniform data collection. Online resources can be found at https://www.mdsgene.org/ .


  • Open Access

    Defining Quality of Life: The Perspective of People Living with Parkinson's Disease

    by Samantha Dorrance, Richa Patel, Glenn T. Stebbins, Jamie L. Adams, Allison M. Allen, Tara Hastings, Soania Mathur, Onanong Phokaewvarangkul, Gary Rafaloff, Rajasumi Rajalingam, et al.

    Background: Little is known about how people with Parkinson's conceptualize “ quality of life .” Objective: To describe the meaning of “ quality of life ” from the perspective of people with Parkinson's. Methods: Participants ( N = 42) were asked “What does the term ‘quality of life’ mean to you?” Definitions were analyzed using inductive qualitative methods. Results: Quality of life is captured in a framework illustrating how activities, experiences, and coping strategies generate positive feelings that collectively shape the mental state that defines quality of life. Conclusions: People with Parkinson's typically define what constitutes a good quality of life, with health status acting as an enabler (or barrier). Multiple factors, varying across individuals and potentially changing with circumstances, shape how people view their quality of life, and offer potential avenues for sustaining it. These personal, subjective and adaptive conceptualizations of quality of life should inform the design of interventions and measurement instruments.


  • Open Access

    It Is Personal: What People with Parkinson's Disease Say Matters Most for Quality of Life

    by Samantha Dorrance, Richa Patel, Glenn T. Stebbins, Jamie Adams, Allison M. Allen, Tara Hastings, Soania Mathur, Onanong Phokaewvarangkul, Gary Rafaloff, Rajasumi Rajalingam, et al.

    Background: Little is known about what matters most for quality of life in people with Parkinson's disease and how much it varies between individuals. Objective: The goal was to define the relative impact of quality of life determinants in people with Parkinson's disease, including variation across individuals and by disease severity, gender, age, and ethnicity. Methods: Sixty‐one factors potentially associated with quality of life in people with Parkinson's disease were identified from the literature and nominated by participants with Parkinson's disease. Forty‐four participants then rated their degree of impact on quality of life from “a lot” to “not at all,” and identified their “top 3 most important” factors. Results: At the individual level, determinants of utmost importance varied greatly, with 39 of 61 factors being reported at least once in the “top 3.” There were 17 factors that at least 50% of the sample agreed affected quality of life “a lot,” and only two were symptoms of the disease. Twelve (all positive experiences) retained at least 50% agreement across subgroups defined by disease severity, age, gender and ethnicity. Symptom‐related factors of high importance varied markedly in mild disease subgroup in particular. Conclusions: Factors that are not direct consequences of the disease, but may be highly personal and interfere with what one finds meaningful, emerged as highly relevant. Symptoms also greatly impacted quality of life for most individuals, but specific symptoms varied across individuals. Quality of life determinants in people with Parkinson's disease appear highly individualized, and currently used measurement tools with fixed items may not be optimal. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    ‘What's in a Name?’ Naming Genetically Determined Movement Disorders: Gap and Controversy

    by Connie Marras, Alberto Albanese, Mark Hallett, Christine Klein, Katja Lohmann, Genetic Nomenclature in Movement Disorders Study Group Steering Committee, H A Jinnah

    In 2016, the International Parkinson and Movement Disorder Society (MDS) Task Force for Genetic Nomenclature in Movement Disorders laid out a new proposal for naming genetically determined movement disorders. This proposal sought to address the difficulties arising from the practical usage of numbered loci (eg, DYT1, DYT2, DYT3, etc.) as names for disorders. The proposal incited commentary highlighting concerns of subjectivity, neglecting relevant non‐movement features, and predicting the need for constant change as knowledge. An evaluation of the use of the nomenclature in the recent peer‐reviewed literature revealed variable implementation across movement phenotypes. The nomenclature has strengths and weaknesses, which are discussed in this article. A consideration of opportunities for improvement is warranted, and weighing the options will be the task of the MDS Nomenclature in Genetic Movement Disorders Study Group. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Frozen in Addiction: A New Wave of Drug‐Induced Movement Disorders?

    by Christos Ganos, Roberto Erro, Mohammad Abdullah, Tanya S. Hauck, Daniel Ciccarone, Christy Sutherland, Parisa Saiyarsarai, Connie Marras, Susan H. Fox, Alfonso Fasano, et al.